Dxcover is an award-winning team, dedicated to developing liquid biopsies for early detection of cancer and other diseases. Dxcover technology is based on the world leading research of Matthew J Baker PhD. We spun out from the University of Strathclyde in 2019 as ClinSpec Diagnostics Limited and rebranded as Dxcover Limited in 2021, by which point we had secured £5.1m of funding. We have successfully completed two ground-breaking clinical studies on detection of brain cancer and are currently developing our platform for the detection of commonly occurring cancers.
Product & Application Notes
The Dxcover Platform is the next-generation of infrared analysis, with the potential to transform the routine analyses of a range of samples. For more information, please see our portfolio of Application Notes.